Protalix Biotherapeutics Inc
PLX
查看详细走势图
1.785USD
+0.055+3.18%
交易中 （美东）报价延迟15分钟
143.41M总市值
23.82市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.18%
5天
-0.28%
1月
+2.00%
6月
+27.50%
今年开始到现在
-5.05%
1年
+1.42%
查看详细走势图
TradingKey Protalix Biotherapeutics Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Protalix Biotherapeutics Inc当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在药品行业排名100/158位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价12.50。中期看，股价处于下降通道。近一个月，市场表现一般，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Protalix Biotherapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
1
位分析师
买入
评级
12.500
目标均价
+618.39%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Protalix Biotherapeutics Inc亮点
亮点风险
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
业绩增长期
公司处于发展阶段，最新年度总收入53.40M美元
估值高估
公司最新PE估值23.08，处于3年历史高位
机构加仓
最新机构持股12.24M股，环比增加6.46%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值1.32M
活跃度降低
近期活跃度降低，过去20天平均换手率0.06
Protalix Biotherapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Protalix Biotherapeutics Inc简介
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
公司代码PLX
公司Protalix Biotherapeutics Inc
CEOBashan (Dror)
网址https://protalix.com/
常见问题
Protalix Biotherapeutics Inc(PLX)的当前股价是多少？
Protalix Biotherapeutics Inc(PLX)的当前股价是 1.785。
Protalix Biotherapeutics Inc的股票代码是什么？
Protalix Biotherapeutics Inc的股票代码是PLX。
Protalix Biotherapeutics Inc股票的52周最高点是多少？
Protalix Biotherapeutics Inc股票的52周最高点是3.100。
Protalix Biotherapeutics Inc股票的52周最低点是多少？
Protalix Biotherapeutics Inc股票的52周最低点是1.320。
Protalix Biotherapeutics Inc的市值是多少？
Protalix Biotherapeutics Inc的市值是143.41M。
Protalix Biotherapeutics Inc的净利润是多少？
Protalix Biotherapeutics Inc的净利润为2.93M。
现在Protalix Biotherapeutics Inc(PLX)的股票是买入、持有还是卖出？
根据分析师评级，Protalix Biotherapeutics Inc(PLX)的总体评级为买入，目标价格为12.500。
Protalix Biotherapeutics Inc(PLX)股票的每股收益（EPS TTM）是多少
Protalix Biotherapeutics Inc(PLX)股票的每股收益（EPS TTM）是0.075。
相关品种
